Pharma Horizons: Artificial Intelligence

Artificial intelligence (AI) and Big Data are set to remain the most disruptive powers in the healthcare sector for the next two years, with Pharma executives prioritizing these innovations for the near future, according to GlobalData.¹

This report delves into some of the major obstacles and the potential for AI in the pharmaceutical industry. Register now to access exclusive content and insight from:

• Dr Vladimir Makarov, Programme Manager, The Pistoia Alliance
• Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos Velez, AI and Life Science consultants
• Dr Gunnar Sachs, Partner (Healthcare and Life Sciences Sector), Clifford Chance
• Francesca Blythe, Josefine Sommer and Zina Chatzidimitriadou, Partners at Sidley Austin LLP.

Stay up to date with the latest developments on AI with articles including:

• AI’s influence on regulatory compliance and clinical development in pharma
• The new European Health Data Space (EHDS) regulation and what it means for the life sciences industry
• How AI is reshaping the regulatory landscape in the late-stage pharmaceutical industry
• Leveraging AI for data integrity and the technology’s impact in the R&D sector.

Interested? Register your details now to download for free today!

This Pharma Horizons report is brought to you in association with:

 

Reference

1. Future of Work in Healthcare – Strategic Intelligence. [Internet] GlobalData. 2025. Available from: https://www.globaldata.com/store/report/future-of-work-in-healthcare-theme-analysis/